Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.
about
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccineVaccines for preventing typhoid feverVaccines for preventing typhoid feverLive attenuated vaccines for invasive Salmonella infectionsComplex adaptive immunity to enteric fevers in humans: lessons learned and the path forwardMucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccineImmunology of Gut Mucosal VaccinesEnteric infections, diarrhea, and their impact on function and development.A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectorsLive recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigenConstitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909Influence of vector-encoded cytokines on anti-Salmonella immunity: divergent effects of interleukin-2 and tumor necrosis factor alphaConstruction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans.Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses.HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines.Partially assembled K99 fimbriae are required for protection.Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human Vaccine productionCharacterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes.Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilinReduced T regulatory cell response during acute Plasmodium falciparum infection in Malian children co-infected with Schistosoma haematobium.Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humansImmunomodulation for prion and prion-related diseases.Bacterial infectious disease control by vaccine development.Live bacterial vaccines--a review and identification of potential hazards.Prevention and self-treatment of traveler's diarrhea.Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.Plant-derived vaccines against diarrhoeal diseases.The use of live attenuated bacteria as a delivery system for heterologous antigens.Could immunomodulation be used to prevent prion diseases?Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humansSalmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid feverIn vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid VaccinesUse of attenuated bacteria as delivery vectors for DNA vaccines.High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans.
P2860
Q21245322-0408CDE7-EA64-492A-BC16-F16D9E9788BAQ24201238-5D6EEEC4-3352-41E7-9ABE-F3896AF850EBQ24244406-CCA8FDEA-FB91-4004-9695-624F81E09C1DQ27003066-F5C1FBE6-C3DA-46E1-82E1-A18ECE028829Q27694492-6D01CE78-5BE6-4321-A151-EB87B961D33EQ28387065-532C5198-BFEF-4E4B-8C15-DA092D442AEDQ28972559-2D9C9C7E-786C-4210-B772-F2089F75626AQ30443288-B645F00E-DFF2-4C83-9B92-E52D5C868200Q33557714-56C28921-2A2A-4A36-8CC6-686FFC2D4639Q33921859-BCD218C6-185E-4DB3-8B80-103D80AC42DBQ34007802-90A1E3FE-A126-4287-9482-5A02F79611F9Q34008045-ADBEAAA1-9028-4B8E-BF51-024019BDCD96Q34008449-2B45DACD-5A8E-46B7-8A73-33B492E1531BQ34008614-D0D7C3FD-6716-454A-BC69-CE05F314F0E9Q34009711-EA63CA3E-97AA-4AA1-9744-C236C64A3859Q34034148-6DA391D6-9174-4E3F-B7DD-451565E2A807Q34070619-04DEC10E-064C-4082-AC25-70EDDC53ED21Q34111838-C98FBFC0-7A82-49FD-92CC-DC201EA53907Q34120959-CB242943-41BD-4CC2-B600-3B75F11DE324Q34125990-0965BFE8-9397-4175-95FE-F4BC6B65F3D3Q34127550-7228938C-F72F-46D2-96A1-69648E360334Q34150914-2E5364EC-001F-4B74-A6F1-A616AB14D928Q34163676-753F0654-6C77-4CFF-8A76-9C58BF104213Q34334202-47CDCB84-2093-4F62-B21C-A815290AAA33Q34562262-988B089A-B0D1-4FE2-BA59-252311B90202Q34565644-A54F7DB2-FAB2-44F0-80F9-50752FAFB293Q34785982-3A1BFAD3-E7D0-4F09-B0FB-E8F4087B33F6Q34974711-ADF44574-B54A-485E-839F-0946FAF68CD1Q34974972-F42E0D57-F136-424A-B972-9DD685B6ED44Q35059006-9089ACFB-A5B6-4EA3-AA73-85D0DF161650Q35729793-DC6CD419-9432-4FA0-9FA8-7901E6B77A75Q35779390-BF9978C0-C762-413A-863B-C8D19DD55417Q35809240-242667D6-F128-4B74-929A-66AF8225612DQ35875915-D49A9ED5-7770-4A8A-9C0A-7B2626205767Q36017715-F1BD61F9-1C99-457D-81A9-5F887A362195Q36313476-6A80CB1E-EFAC-431A-9DB9-12E9E9EEF457Q36601934-3BBE0531-0EA2-4545-B276-EB396E3B4809Q36728805-9DC1F9CC-A7FE-4341-8F1A-C2A5DB92ED85Q36776046-E7D6D05B-866C-40DA-9E0B-9B33FAE5B7D8Q36854773-E5600823-D4F9-4A3A-A90C-6F2302B088A4
P2860
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@ast
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@en
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@nl
type
label
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@ast
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@en
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@nl
prefLabel
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@ast
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@en
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@nl
P2093
P2860
P1476
Phase 2 clinical trial of atte ...... D 908-htrA in U.S. volunteers.
@en
P2093
C O Tacket
G Losonsky
J P Nataro
K L Kotloff
M B Sztein
M M Levine
P2860
P304
P356
10.1128/IAI.68.3.1196-1201.2000
P407
P577
2000-03-01T00:00:00Z